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Hematogenous dissemination represents a common manifestation of squamous cell
carcinoma of the head and neck, and the recommended therapeutic options usually
consist of systemically administered drugs with palliative intent. However, mounting
evidence suggests that patients with few and slowly progressive distant lesions of small
size may benefit from various local ablation techniques, which have already been
established as standard-of-care modalities for example in colorectal and renal cell
carcinomas and in sarcomas. In principle, serving as radical approaches to eradicate
cancer, these interventions can be curative. Their impact on local control and overall survival
has been shown in numerous retrospective and prospective studies. The term
oligometastatic refers to the number of distant lesions which should generally not
surpass five in total, ideally in one organ. Currently, surgical resection remains the
method of choice supported by the majority of published data. More recently,
stereotactic (ablative) body radiotherapy (SABR/SBRT) has emerged as a viable
alternative. In cases technically amenable to such local interventions, several other clinical
variables need to be taken into account also, including patient-related factors (general health
status, patient preferences, socioeconomic background) and disease-related factors
(primary tumor site, growth kinetics, synchronous or metachronous metastases). In head
and neck cancer, patients presenting with late development of slowly progressive
oligometastatic lesions in the lungs secondary to human papillomavirus (HPV)-positive
oropharyngeal cancer are the ideal candidates for metastasectomy or other local therapies.
However, literature data are still limited to say whether there are other subgroups benefiting
from this approach. One of the plausible explanations is that radiological follow-up after
primary curative therapy is usually not recommended because its impact on survival has not
been unequivocal, which is also due to the rarity of oligometastatic manifestations in this
disease. At the same time, aggressive treatment of synchronous metastases early in the
disease course should be weighed against the risk of futile interventions in a disease with
already multimetastatic microscopic dissemination. Therefore, attentive treatment
sequencing, meticulous appraisal of cancer extension, refinement of post-treatment
surveillance, and understanding of tumor biology and kinetics are crucial in the
management of oligometastases.
Keywords: head and neck cancer, oligometastatic, metastasectomy, surgery, stereotactic ablative body
radiotherapy, immunotherapy, surveillance, cureDecember 2020 | Volume 10 | Article 6177931
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Recent therapeutic achievements in head and neck cancer
managed to reduce the risk of death from recurrences and
metastatic dissemination or at least contributed to delaying
disease progression and quality of life deterioration. Apart
from new systemic modalities leveraging the immune cells to
combat cancer, increasing attention has been drawn towards
local ablative approaches, which either as complementary or
stand-alone therapies demonstrated encouraging activity against
distant lesions. In particular, cases with few slowly growing
metastases seem to constitute the ideal candidates (1). These
patients present with different forms of oligometastatic disease.
Besides a de-novo diagnosis, it may develop in the context of a
controlled primary tumor (oligorecurrence) or otherwise
controlled polymetastatic disease (oligoprogression). Herein,
we will discuss the current state of the art in management of
oligometastatic head and neck cancer in order to assist
physicians in finding the optimal spot in the disease course
where such treatment brings the maximum benefit to patients.
However, before doing that, we will briefly review some
important facts about metastatic outgrowth defining the
patients at risk, addressing different diagnostic methods, and
introducing available treatment options.DISTANT METASTASES: WHO, HOW,
AND WHAT
Who is at risk of developing distant lesions? Compared with other
malignancies, the proportion of head and neck cancer
patients presenting with hematogenous dissemination is
generally smaller and varies from 3%–17% at presentation
(before any therapy). This may increase during the course of
the disease to 10%–40% and can be even found higher at autopsy
studies (40%–50%). The clinical presentations are variable
according to the primary tumor site, disease stage, local and
regional control, duration of follow-up, histological type, and
delivered treatment. High-risk features include hypopharyngeal
origin, advanced locoregional disease characterized by large
tumors and extensive lymphadenopathies, poor histological
differentiation, and the presence of extracapsular spread (2).
Moreover, advanced age, black race, and radiological evidence of
low jugular, posterior triangle, paratracheal, and contralateral
lymph nodes were associated with increased risk of metastases (3,
4). The aforementioned features hold true for the most frequent
histological type, i.e. squamous cell carcinoma, which will also be
the principal subject of this article unless otherwise specified.
Furthermore, some tumors both within this group, such as
basaloid squamous cell carcinoma, and beyond, such as
nasopharyngeal, adenoid cystic, and neuroendocrine
carcinomas, are known for even a higher propensity to develop
distant lesions (5). Typically involved sites are the lungs (70%–
85% of patients with metastases), albeit a distinction from a
primary pulmonary tumor can be challenging, then the bones
(15%–39%) and liver (10%–30%), while skin (10%–15%) andFrontiers in Oncology | www.frontiersin.org 2brain (about 5%) affections remain less frequent (2). They usually
occur within 2–3 years of diagnosis with the notable exception of
a small proportion (probably more than 10%) of human
papillomavirus (HPV)-positive oropharyngeal cancer cases,
which continue to metastasize for a longer period of time, even
beyond 6 years (6, 7). Interestingly, in a recent meta-analysis of
seven studies, time to distant progression was 0.2–106 months
and 0.2–33 months in HPV-positive and HPV-negative
oropharyngeal cancer patients, respectively (8).
How to detect them? This is the pivotal question because
imaging modalities differ in their diagnostic accuracy, which is
partially responsible for the higher incidence of macrometastases
found at autopsies than radiological surveys (5). In addition, our
knowledge of micrometastases sometimes identified in tissue
specimens remains elusive, including their clinical significance.
Currently, fluorine-18-fluorodeoxyglucose (FDG) positron
emission tomography with or without simultaneous computed
tomography (PET/CT) scanning represents the optimal modality
for detection of head and neck cancer distant spread at initial
staging (9, 10). In a prospective trial of 233 patients, the addition
of FDG-PET to a conventional work-up (physical examination,
head and neck CT or magnetic resonance [MR], and thoracic
CT) changed the M-stage in 8.6% of the study cohort (11). On
the other hand, its role in follow-up of head and neck cancer
survivors has been proved only for an early evaluation of regional
control after definitive chemoradiotherapy but still needs to be
defined for metastatic disease (12–14). One of the new,
promising techniques that could find its place especially in
surveillance protocols is liquid biopsy. It is based on early
detection of circulating tumor deoxyribonucleic acid (DNA)
mostly in the blood but also in saliva and other body fluids
(15). Finally, special attention should be paid to patients with
polymetastatic disease on systemic therapy, in whom close
response monitoring by CT or PET/CT scans is usually
performed every 6 to 12 weeks for a timely detection of disease
progression, which in some highly selected cases may be treated
with local ablation.
What are the treatment options? Although the traditional
approach of oncology care in patients with metastatic tumors
relies on systemic treatment with palliative intent, mounting
evidence has demonstrated the utility of local ablation in certain
clinical situations. Surgical resection of metastases, especially in
the lungs, has been known to medical professionals since the 19th
century. In 1882, Weinlechner removed sarcoma metastases
localized near the primary tumor infiltrating the thoracic wall.
However, the first pulmonary metastasectomy as a planned and
separate procedure was carried out by Divis in Prague in 1926
(16). When in 1995 Hellman and Weichselbaum thus coined the
term “oligometastatic state”, surgery had already been widely
accepted as a curative approach to a rather small proportion of
patients, typically with lung metastases from soft tissue sarcomas,
osteosarcomas, and renal cell cancers and with hepatic
metastases from colorectal cancer (17). More recently, the
armamentarium of local approaches has been complemented
by radiotherapy and thermal ablation treatments, such as
radiofrequency ablation or cryotherapy, which spare patientsDecember 2020 | Volume 10 | Article 617793
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margins. At present, patients with oligometastatic disease of
various origins are routinely offered such a potentially curative
treatment, sometimes using a sequential combination of different
modalities, planned in a stepwise fashion andeven repeatedly in the
case of accessible recurrences (18, 19).APPROACH TO OLIGOMETASTATIC
DISEASE
Over the past year, growing efforts have been undertaken to define
oligometastatic disease and its different states in order to
standardize reporting thereof (20, 21). As a result, the following
two conditions must be met: the maximum number of five
metastases should not be surpassed, and all of them must be
safely treatable, whereas a controlled primary is optional (21).
According to the timing of its appearance, several distinct clinical
presentations, discussed further in the text, are recognized (20–22).
Since a standard approach has not been determined in these
situations, all patients who could potentially be considered for a
local approach should be discussed in multidisciplinary tumor
boards. In this regard,wepropose amultistep evaluationprocedure
respectingnotonly the technical feasibility of a givenprocedurebut
also its clinical relevance (Figure 1). While the former aspect is
beyond the scope of this paper, we will address important pre-
treatment factorshere, someofwhichare specific forheadandneck
cancer, and then outline the main treatment modalities, among
which the surgical approach is grounded in the strongest body of
scientific evidence, followed by stereotactic radiotherapy reserved
for inoperable cases. In the last section, we will deliberate over the
intriguing role of combining systemic treatment with local
therapies. The key message is that primary intent of these
therapeutic endeavors is curative, although they may also be
beneficial in consolidating response to systemic palliative
treatment or postponing initiation or change thereof. Finally, the
advantages of active approach should be weighed against watchful
waiting, particularly in heavily pre-treated patients with repeatedly
recurring and slowly progressing oligometastases.
Clinical Pre-Treatment Considerations
The following three patient-related factors should be
acknowledged before performing a planned intervention,
feasible from a technical point of view.
General health status. The majority of head and neck cancer
cases occur in the elderly, and global epidemiological projections
predict increasing proportions of older people, people with
cancer, and also older people with head and neck cancer,
which further stimulates the strengthening position of geriatric
evaluation in oncology practices. Prior to a tumor-directed
treatment, all cancer patients of 70 years of age or older should
undergo a frailty screening test and, according to the result, be
subjected to a comprehensive geriatric assessment comprising a
thorough evaluation of functional status, comorbidities,
cognition, nutritional status, social support, psychological state,
and polypharmacy (23). These variables are relevant, albeit toFrontiers in Oncology | www.frontiersin.org 3lesser extent, to the younger counterparts as well, who have
usually an overall higher life expectancy and functional reserve
capacity, so that the medical assessment is often limited to the
appraisal of performance status and comorbidities (24). Of note,
frailty, characterized by at least three of the following five criteria:
weakness (grip strength), slowness, low physical activity,
exhaustion, and weight loss, or pre-frailty (comprising only
one or two of these criteria) can develop even in younger
patients, particularly in the presence of chronic diseases,
socioeconomic deprivation, and specific lifestyle behaviors
(smoking, obesity) (25). Estimating overall health status of an
individual and detecting unknown deficits help select an
appropriate local therapy and decide on its timing and possible
combinations with systemic treatment.
Patient preference. Shared-decision making with a well-
informed patient should be encouraged whenever possible and
has particular importance in borderline cases, such as when
watchful waiting is proposed. Sometimes, patients can decide
whether they opt for an invasive procedure or radiotherapy or
thermal ablation if assumed equipotent in a given situation.
Socioeconomic background. It has been well recognized that
socioeconomic and other disparities negatively impact on cancer
incidence and survival due to associated inequalities in harmful
lifestyle behaviors (smoking, alcohol intake, dietary patterns,
physical inactivity), screening, and treatment (26). In head and
neck cancer, lower income, high school education or less, and
older age correlate with decreased overall and disease-free
survival, at least in the USA (27). All these factors are
particularly relevant in resource-limited countries. Moreover,
the COVID-19 pandemic has disrupted oncologic care in
many areas and amplified the pre-existing gap in its delivery (28).
In order to optimize the planned therapeutic intervention, the
following three disease-related factors should be taken into
account in patients deemed suitable according to the above-
mentioned characteristics.
Primary tumor site. Among squamous cell carcinomas of the
head and neck, HPV-positive oropharyngeal cancer represents a
separate entity with distinct biological and epidemiological
behavior (29). Not only is overall survival after distant failure
longer in these patients, but about one third of oligometastatic
cases in the lungs can be cured with either surgery or radiotherapy
(7, 30). Noteworthy, compared with their HPV-negative;
counterparts, patients with HPV-positive oropharyngeal cancer
present more often with dissemination to more than two organs
(about one third of cases) that can also involve unusual
localizations such as the skeletal muscles, pericardial lymph
nodes, kidney, or pancreatic tail (6–8). Therefore, careful
evaluation and sometimes even multiple biopsies are warranted
in these cases. Another notable exception sharing with HPV-
positive oropharyngeal cancer the prominent trend of developing
distant metastases is nasopharyngeal carcinoma (31). Although
less evidence is available on using local ablation alone to treat
metastatic lesions in nasopharyngeal carcinoma, improved
outcomes have been noted if palliative systemic therapy for
disseminated disease is complemented with radiotherapy of the
primary lesion (32, 33).December 2020 | Volume 10 | Article 617793
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decision-making factors in patients presenting with distant
spread (34). When applying local ablation to eradicate a
disseminated cancer, the major concern is that the few visible
macroscopic lesions represent merely the inception of an
explosive manifestation. Logically, a follow-up imaging in 2–3
months gives us the desired answer but that’s actually what we
try to avoid doing in the majority of cases, if not deemed suitable
candidates for a wait-and-watch strategy, due to the following
three reasons. First, lesions that can be treated now may progress
in a couple of months in size rendering them unsuitable for the
initially planned procedure. Second, new distant lesions may
develop, and third, the patient’s condition may alter, either
because of disease progression or underlying comorbidities, to
an extent which can contraindicate further antitumor efforts. In
some cases, distant metastases, particularly in the lung
parenchyma, can be traced back on preceding imaging
methods carried out even for other, non-oncologic reasons. In
other cases, we may encounter oligoprogression which means
that one or a few nodules progress during systemic palliative
therapy while at the same time multiple other lesions remain
under control. Subsequently, retrospective review of tumor size
and other characteristics will help estimate the disease kinetics.
However, in the majority of patients, the decisive factor is
whether the metastases were detected at the time of initial
diagnosis or whether they appeared in the course of the
disease. These aspects are detailed in the following paragraph.
Synchronous or metachronous metastases. In the former
scenario, partially owing to the insufficient information onFrontiers in Oncology | www.frontiersin.org 4tumor kinetics, patients usually receive systemic treatment
in the first place, and if the disease is well-controlled, a local
therapy is delivered at some point later. In the latter setting,
corresponding to oligorecurrence or oligoprogression, a series of
imaging studies is sometimes available allowing a more accurate
appraisal of the disease pace and facilitating decisions about a
single-modality local therapy. According to an arbitrary
definition, metachronous metastases occur after 3 months from
the initial diagnosis, which typically means that at least one
radiological survey had been carried out. In this respect, it should
be noted that in the majority of head and neck cancer patients
treated with curative intent, no radiological surveillance is
recommended as it had not consistently demonstrated survival
benefit, although this does not perhaps hold true for some patient
subgroups, such as with HPV-positive oropharyngeal cancer, in
whom periodic imaging might be warranted (14).
Surgical Treatment
Supported by the largest body of evidence, metastasectomy has
been traditionally considered the gold standard in this setting. In
2015, a meta-analysis of 11 retrospective studies enrolling a total
of 387 head and neck cancer patients calculated a 5-year overall
survival rate at 29% after resection of metachronous pulmonary
metastases (mostly single nodules). Various poor prognostic
factors were reported in the included individual studies
comprising the site of the primary tumor in the oral cavity,
initial lymph node involvement, shorter interval from primary
diagnosis to pulmonary dissemination, particularly if it occurred
within 1 year, incomplete metastasectomy, and multipleFIGURE 1 | Multistep process of decision making in oligometastatic head and neck cancer patients. Patients with suspected hematogenous spread should be
discussed at tumor board meetings in order to decide whether a biopsy confirmation is needed and whether local ablation can be proposed in case of an
oligometastatic manifestation. Such treatment should not only be technically feasible but also clinically sound. Metastasectomy remains the treatment of choice and
could be replaced by stereotactic body radiation or other local therapies in patients not suitable for a surgical intervention. Incorporating chemo- or immunotherapy
or both, systemic treatment can be combined with local ablation according to the clinical setting. Watchful waiting is reserved for highly selected cases, usually as a
temporary solution in heavily pre-treated patients with known disease kinetics.December 2020 | Volume 10 | Article 617793
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is less advanced but 5-year survival after resection of hepatic
oligometastases may be in the same range (36). Additionally, the
importance of new techniques should be brought to the
forefront. In a retrospective cohort of different primary tumors,
minimally invasive approaches, such as video-assisted thoracic
surgery (VATS) and radiofrequency ablation (RFA), were
associated with lower morbidity and similar local control and
overall survival compared with an open resection (37). Besides
that, surgical candidates are usually young patients in a good
general condition, and this should also be kept in mind not only
when making decisions in routine clinical practice but also when
interpreting the results of available retrospective studies. Finally,
the obtained full pathological specimen provides definitive
diagnosis as well as additional material for immunohistochemical
andmolecular analyses if soneeded. In this respect, differentiating a
pulmonary metastasis from squamous cell lung carcinoma has
been challenging and requires clinical and radiological inputs and
in the case of oropharyngeal carcinoma also detection of high-risk
HPV infection and not only p16 expression which can also be
found in squamous cell carcinomas originating in the lungs,
esophagus, and skin (38, 39).
Radiotherapy
In patients who are unwilling or unable to undergo an invasive
procedure or deemed to be at high risk of postoperative
complications due to underlying comorbidities, stereotactic
(ablative) body radiotherapy (SABR/SBRT) has emerged as a
viable alternative to a standard surgical intervention. Derived
from intracranial stereotactic radiosurgery, the methodology was
introduced to clinical practice by Lax and Blomgren at the
Karolinska Hospital in Sweden in September 1991 (40, 41).
Based on delivering precisely targeted high doses of radiation
in one or several fractions, the concept of SABR has been rapidly
adopted by many institutions to treat mainly small lung cancers
either primary or secondary, liver metastases, and later on also
bone, lymph node, and other less frequent locations (42, 43). The
increasing popularity has been mirrored by a steadily rising
implementation in treatment protocols which is expected to
continue in the coming years (44). Multiple single-arm studies
as well as several randomized trials showed that SABR can
improve disease-free and overall survival in the oligometastatic
setting while maintaining good tolerance (45–51). However,
covering different primary tumor types and organ sites, the
available data remain heterogeneous (44). Furthermore, no
randomized trial comparing a standard surgical approach with
SABR has been conducted so far.
Until now, the largest retrospective study in head and neck
cancer evaluated 82 cases of different histological types
presenting either with synchronous or metachronous
oligometastases (less than three in total) or multiple metastases
in the lungs. Among 43 patients with oligometastatic squamous
cell carcinomas, 1- and 2-year local control was 96% and 90%,
respectively, and 1- and 2-year overall survival was 74% and 66%,
respectively (52). Focusing solely on oligometastatic disease,
another retrospective study reported 1- and 2-year overallFrontiers in Oncology | www.frontiersin.org 5survival of 78% and 43%, respectively, in 27 squamous head
and neck carcinoma patients with up to five synchronous and
metachronous metastases mostly affecting the lungs but also
other organs encompassing the bones, liver, lymph nodes, and
soft tissues. Local control of treated lung nodules was 74% and
52% at 1- and 2-years, respectively (53). Contrary to the former
study, in which histopathological confirmation of the lung
lesions was obtained in almost 90% of cases, in the latter one,
biopsy was not mandatory prior to radiotherapy.
Regarding prospective trials on the efficacy and safety of SABR
in oligometastatic disease, only a few are randomized phase II
trials while most of them are single arm studies with just a small
number of head and neck cancer patients (54, 55). In the largest
one, Sutera et al. recruited 147 patients with up to five
metachronous, biopsy-proven metastases visualized on FDG-
PET/CT in at most three organs comprising the lungs (52%),
lymph nodes (17%), bones (15%), and other sites. There was a
large variety of primary tumors with more than half of them
represented by lung cancer (22%), colorectal cancer (21%), and
head and neck cancer (11%). Owing to an excess of early deaths,
median overall survival of 17.6 months in 16 patients with head
and neck cancer, out of which 11 had squamous cell carcinoma,
was inferior to that observed in other primary tumor subgroups.
However, the 42% 5-year overall survival yielded in this cohort
compares favorably to outcomes yielded in surgical studies but
can be biased by the small patient number (43). As of yet, the
only randomized trial exploring the addition of SABR to a
standard systemic palliative treatment according to primary
cancer was the SABR-COMET phase II study with a 2:1
randomization in favor of the experimental arm. Oligometastatic
state was defined by amaximum offivemetachronous lesions with
not more than three of them per organ. Biopsy was optional, and
participants were not considered candidates for surgery. The three
most frequently included primary tumors were breast cancer
(18%), colorectal cancer (18%), and lung cancer (18%), which
were not balanced between the two study arms. The number of
head and neck cancer patients was not specified except for a short
comment in the supplementary materials on a case of
oropharyngeal cancer treated for a lung metastasis of 3 cm in
diameter complicated by a large pulmonary abscess a year later. In
the whole cohort of 99 patients, SABR enhanced 5-year overall
survival from 18% to 42% which is very much in line with the
previous study that reported this parameter at 43% for the entire
study population. The benefit observed in SABR-COMET came at
the cost of increased grade 2 or worse treatment-related toxicity
(29% versus 9%) including grade 5 adverse events (5% versus 0%),
albeit with no impact on quality of life as measured using the
FACT-G scores (48, 49). These results are encouraging and imply
that even poor performance and frail patients may be considered
for SABR. Nevertheless, such assumption needs to be validated in
further trials involving a larger proportion of oligometastatic head
and neck cancer patients.
Systemic Treatment
In the case of recurrent head and neck cancer not amenable
to resection or irradiation, palliative systemic therapy canDecember 2020 | Volume 10 | Article 617793
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sufficient criterion for this treatment, and the available
registration trials did not allow consideration of local ablative
methods for their management. At present, patients are usually
treated with various combinations of traditional cytotoxic drugs
(5-fluorouracil, platinum, taxanes) and targeted agents
(cetuximab) including also immune checkpoint inhibitors
(pembrolizumab, nivolumab) according to clinical factors
(biological age, disease burden, pace of the disease) and
programmed cell death ligand-1 (PD-L1) expression and
depending also on previous treatment lines. Interested readers
are referred to two of our recent publications (1, 34). Here, we
would like to point out that if treated with immunotherapy in
first line, patients achieve median overall survival slightly
exceeding 1 year but about one third of them can still be alive
at 3 years (56). Longer follow-up data are not available yet. It is
also not clear whether such treatment can indeed lead to cure,
and if so, then in what proportion of patients. Concerning
second-line immunotherapy, only less than 10% of patients
survive 3 years (57). Importantly, no studies have shown that
postponing the initiation of systemic therapy has any impact on
outcome, which holds true especially for indolent and slowly
progressive cases, creating thus a window of opportunity for
example for local ablation strategies (34, 58).
Combination Approaches
From the above mentioned it follows that combination of local
and systemic approaches might be feasible and beneficial in
terms of survival parameters. Even though rigorous evidence for
that is lacking, a retrospective analysis of the National Cancer
Data Base provided an indirect support by identifying patients
with metastatic squamous cell carcinoma of the head and neck
cancer who received systemic drugs with or without locoregional
therapy. With a median follow-up of 52 months, 3,269 cases were
included. In propensity score-matched cohorts, 2-year overall
survival was significantly enhanced in the combined treatment
arm (34% versus 21%, p<0.001). Notably, the improvement
pertained merely to those who underwent high-intensity
locoregional therapy (oncologic resection or at least 60 Gy of
radiotherapy) and was more pronounced if such intervention
was delivered early in the disease course, i.e. within the first 6
months of diagnosis than later (adjusted hazard radio: 0.26
versus 0.62) (59). These outcomes suggest the importance of
not only treating the locoregional disease adequately but at the
same time also synchronous metastases, opening thus avenues
for possible integration of their ablation in the management of
otherwise locally or locoregionally advanced disease. In this
respect, induction chemotherapy may be followed by definitive
chemoradiation or resection of the primary tumor with
subsequent local ablation of the distant lesion or lesions if they
remain well-controlled throughout the treatment (60). On the
other hand, different concepts pertain to metachronous
presentation. Here, local ablation can be used in parallel to
immuno- and/or chemotherapy either to delay a change of
systemic treatment line in oligoprogressive disease or as oligo-
consolidation in responding patients to eradicate a few persisting
nodules (22, 61).Frontiers in Oncology | www.frontiersin.org 6Another area of research relates to the radiation-induced
bystander effect, also known as the abscopal effect, which is
characterized by regression of nonirradiated distant lesions (62).
This phenomenon is very rare but has recently been brought
back to the spotlight due to a possible synergism with immune
checkpoint inhibitors (63). It is therefore of interest to explore
the beneficial effect of immunotherapy combined with SABR in
oligometastatic disease. A phase II trial of ipilimumab, a
cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, and
sequential or concurrent SABR to metastatic lesions of the
lungs or liver demonstrated disease control in nonirradiated
tumor volume of 26% in 95 patients evaluable for response with
the highest rate of 42% observed after sequential SABR to one
lung lesion. This trial did not focus on oligometastatic disease but
possibly enrolled some of these patients. There were only four
cases of squamous head and neck carcinoma, and all of them
progressed (64). The absence of radiological signs of an abscopal
effect in head and neck cancer was very recently corroborated in
a randomized phase II trial investigating the addition of SABR to
the anti-PD-1 agent nivolumab (65). However, another report
described two polymetastatic head and neck cancer patients in
whom the addition of SABR to PD-1/PD-L1 inhibitors induced
an abscopal effect with an overall tumor regression (66).
Therefore, further confirmation is clearly needed before
accepting the abscopal effect might have clinical relevance.CLINICAL PRACTICE CONTROVERSY
Despite the advantages of local ablation across different tumor
types, the applicability in head and neck cancer remains to be
established. Its role in the management of synchronous
metastases still cannot be generalized, and radiological post-
treatment follow-up in the primary disease setting in search for
metachronous metastases has not been uniformly recommended
in clinical practice because of its controversial impact on patient
survival and the resulting low cost-effectiveness (14). However,
oligometastatic disease amenable to local treatment tends to be
asymptomatic due to its typical localization in the lungs, a
paucity of nodules by definition, and their limited size and
appears preferably late after the initial diagnosis. Such
manifestation of cancer outgrowth can thus be detected only
on imaging modalities, performed either as part of radiological
surveillance, notwithstanding its unclear pertinence, or perhaps
less frequently for other reasons.
As a result, the key issue is to define patient populations who
should be exposed to a regular radiological assessment in order to
be potentially able to undergo an aggressive local treatment with
curative intent, acknowledging at the same time all the individuals
who take these preventivemeasures in vain either because they will
never become metastatic or will develop a distant recurrence not
eligible for local treatment because of various patient- and disease-
related factors. Moreover, even if a patient finally receives local
ablation, it does not automatically mean cure, and in this difficult
patient population, the majority of which had undergone bi- or
trimodality treatment, severe late adverse events may sometimes
have even more debilitating and life-threatening consequencesDecember 2020 | Volume 10 | Article 617793
Szturz et al. Oligometastatic Disease Managementthan disease recurrence. We also need to understand that
local therapy of hematogenous dissemination is rarely applied in
head and neck cancer patients. Among 934 oropharyngeal cancer
cases initially managed with radiotherapy with or without
chemotherapy, 15% were later diagnosed with distant metastases,
4%hadoligometastases (notmore thanfive lesions confined to one
organ), and disease-free survival of 1.9 to 7.7 years was seen in 10
patients (1% of the initial cohort), all of which had pulmonary
oligometastases treated in90%with local therapies.Ofnote, nine of
these 10 cases were HPV-positive (30).CONCLUSIONS
Local ablation of oligometastases gives a second chance of long-
term survival to patients failing primary curative treatment,
especially with colorectal and renal cell carcinomas and
sarcomas. In head and neck cancer, the evidence for such benefit
is less clear, and this treatment is rarely delivered in clinical
practice. We still need to figure out who will derive most benefit,Frontiers in Oncology | www.frontiersin.org 7when the right moment is to intervene, and how to optimize our
diagnostic modalities for a timely identification of potential
candidates. Despite this level of uncertainty and a lack of
randomized trials, we advocate using this approach in selected
patients after a discussion at a multidisciplinary tumor board. At
the same time,wewould like to stress the importanceof conducting
dedicated studies for squamous head and neck carcinoma patients,
particularly with HPV-positive oropharyngeal cancer. A direct
comparison between surgery and SABR in fit patients seems to be
indispensable for further improvement as is resolving the question
of implementing local ablation early in the disease course, possibly
with the help of innovative approaches to disease kinetics
measurements in order to exclude an early phase of an explosive
distant spread.AUTHOR CONTRIBUTIONS
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